EP1322779A4 - Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids - Google Patents

Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids

Info

Publication number
EP1322779A4
EP1322779A4 EP01970982A EP01970982A EP1322779A4 EP 1322779 A4 EP1322779 A4 EP 1322779A4 EP 01970982 A EP01970982 A EP 01970982A EP 01970982 A EP01970982 A EP 01970982A EP 1322779 A4 EP1322779 A4 EP 1322779A4
Authority
EP
European Patent Office
Prior art keywords
hiv
aids
treatment
methods
protease inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01970982A
Other languages
German (de)
French (fr)
Other versions
EP1322779A2 (en
Inventor
Neil T Parkin
Rainer A Ziermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monogram Biosciences Inc
Original Assignee
Virologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/663,458 external-priority patent/US7186506B1/en
Application filed by Virologic Inc filed Critical Virologic Inc
Publication of EP1322779A2 publication Critical patent/EP1322779A2/en
Publication of EP1322779A4 publication Critical patent/EP1322779A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP01970982A 2000-09-15 2001-09-14 Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids Withdrawn EP1322779A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/663,458 US7186506B1 (en) 2000-06-12 2000-09-15 Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US663458 2000-09-15
PCT/US2001/028754 WO2002022076A2 (en) 2000-09-15 2001-09-14 Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids

Publications (2)

Publication Number Publication Date
EP1322779A2 EP1322779A2 (en) 2003-07-02
EP1322779A4 true EP1322779A4 (en) 2005-04-20

Family

ID=24661900

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01970982A Withdrawn EP1322779A4 (en) 2000-09-15 2001-09-14 Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids

Country Status (4)

Country Link
EP (1) EP1322779A4 (en)
AU (1) AU2001290923A1 (en)
CA (1) CA2422815A1 (en)
WO (1) WO2002022076A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE302287T1 (en) 1999-05-28 2005-09-15 Virco Nv NEW MUTATION PROFILES OF HIV-1 REVERSE TRANSCRIPTASE IN ASSOCIATION WITH PHENOTYPIC DRUG RESISTANCE
US7186506B1 (en) 2000-06-12 2007-03-06 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US7138231B2 (en) * 2000-09-15 2006-11-21 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US6869759B1 (en) 1999-06-22 2005-03-22 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
EP1356082A2 (en) 2000-10-20 2003-10-29 Virco Bvba Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
US7384734B2 (en) 2002-02-15 2008-06-10 Monogram Biosciences, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
CA2490862A1 (en) 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
AU2003256460A1 (en) 2002-07-01 2004-01-19 Virologic, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
AU2003251732B2 (en) 2002-07-01 2008-09-18 Tibotec Pharmaceuticals Ltd. New mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
WO2004003512A2 (en) * 2002-07-01 2004-01-08 Virologic, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
CA2688278A1 (en) 2007-05-25 2008-12-04 Tibotec Pharmaceuticals New mutational profile in hiv-1 gag cleavage site correlated with phenotypic drug resistance

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078996A1 (en) * 1999-06-22 2000-12-28 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078996A1 (en) * 1999-06-22 2000-12-28 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CONDRA J H ET AL: "IN VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 374, 6 April 1995 (1995-04-06), pages 569 - 571, XP001026179, ISSN: 0028-0836 *
JACOBSEN HELMUT ET AL: "In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies", JOURNAL OF INFECTIOUS DISEASES, vol. 173, no. 6, 1996, pages 1379 - 1387, XP009040350, ISSN: 0022-1899 *
PETROPOULOS C J ET AL: "A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 44, no. 4, April 2000 (2000-04-01), pages 920 - 928, XP002962272, ISSN: 0066-4804 *
ZIERMANN R ET AL: "A MUTATION IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE, N88S, THAT CAUSES IN VITRO HYPERSENSITIVITY TO AMPRENAVIR", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 9, May 2000 (2000-05-01), pages 4414 - 4419, XP002908352, ISSN: 0022-538X *

Also Published As

Publication number Publication date
WO2002022076A2 (en) 2002-03-21
EP1322779A2 (en) 2003-07-02
CA2422815A1 (en) 2002-03-21
WO2002022076A3 (en) 2003-03-27
AU2001290923A1 (en) 2002-03-26

Similar Documents

Publication Publication Date Title
ZA200201161B (en) Methods of treating nuclear factor-kappa B mediated diseases and disorders.
AU7186501A (en) Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
IL157577A0 (en) Disposable underpants and method of providing the same
EP1194587A4 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
AU3947902A (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
HUP0500560A3 (en) Mixtures of mushroom enzymes and the use thereof for treating maldigestion
IL151946A0 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
AU2003278816A8 (en) Ss-l-2'-deoxynucleosides for the treatment of resistant hbv strains and combination therapies
EP1392292A4 (en) Pyranoindazoles and their use for the treatment of glaucoma
EP1015642A4 (en) Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
AU8136801A (en) Methods of preventing or treating diseases and conditions using complex carbohydrates
EP1322779A4 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
AU7122801A (en) New aporphine esters and their use in therapy
AU5754701A (en) Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
EP1463495A4 (en) Agents and methods for treatment of cancer
EP1320402A4 (en) Hemorrhoid treatment and prostate massage apparatus
AU7516601A (en) Methods of treating viral diseases with il-18 and il-18 combinations
EP1359975A4 (en) Ocular iontophoretic device and method of use
AU2001266863A1 (en) Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
IL153769A0 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
AUPQ582400A0 (en) A method of treatment and agents for use therein
IL151493A0 (en) Use of dermaciclane for the treatment of anxiety and depression
PL354111A1 (en) Combined therapy for treating the both depression and anxiety
HUP0302882A3 (en) Improved specificity in treatment of diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030414

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7G 01N 33/569 B

Ipc: 7C 12Q 1/70 B

Ipc: 7C 12Q 1/68 B

Ipc: 7C 12Q 1/18 A

A4 Supplementary search report drawn up and despatched

Effective date: 20050302

17Q First examination report despatched

Effective date: 20050412

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051025